MassMutual Private Wealth & Trust FSB Acquires 156 Shares of HCA Healthcare, Inc. $HCA

MassMutual Private Wealth & Trust FSB boosted its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 32.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 642 shares of the company’s stock after purchasing an additional 156 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in HCA Healthcare were worth $246,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Avantax Advisory Services Inc. raised its stake in HCA Healthcare by 0.4% during the first quarter. Avantax Advisory Services Inc. now owns 8,077 shares of the company’s stock worth $2,791,000 after acquiring an additional 32 shares in the last quarter. Glenview Trust co raised its position in HCA Healthcare by 2.3% in the 1st quarter. Glenview Trust co now owns 1,451 shares of the company’s stock valued at $501,000 after buying an additional 32 shares during the last quarter. Horizon Investments LLC boosted its stake in shares of HCA Healthcare by 1.1% during the 1st quarter. Horizon Investments LLC now owns 3,175 shares of the company’s stock worth $1,097,000 after acquiring an additional 33 shares during the period. Catalyst Financial Partners LLC boosted its stake in HCA Healthcare by 4.3% in the 1st quarter. Catalyst Financial Partners LLC now owns 872 shares of the company’s stock valued at $301,000 after purchasing an additional 36 shares during the period. Finally, RWA Wealth Partners LLC lifted its position in shares of HCA Healthcare by 2.0% during the 1st quarter. RWA Wealth Partners LLC now owns 1,904 shares of the company’s stock valued at $658,000 after acquiring an additional 37 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Trading Up 0.4%

Shares of HCA Healthcare stock opened at $400.95 on Friday. The firm has a market cap of $93.82 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 1.26 and a beta of 1.41. The business has a 50-day moving average price of $384.69 and a 200-day moving average price of $365.16. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $420.98.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts’ consensus estimates of $6.20 by $0.64. The firm had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Equities research analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th will be given a $0.72 dividend. The ex-dividend date is Tuesday, September 16th. This represents a $2.88 annualized dividend and a yield of 0.7%. HCA Healthcare’s dividend payout ratio (DPR) is currently 12.11%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Royal Bank Of Canada lowered their target price on HCA Healthcare from $404.00 to $401.00 and set an “outperform” rating for the company in a report on Monday, July 28th. JPMorgan Chase & Co. increased their price target on HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a research report on Monday, August 4th. Barclays lifted their price objective on HCA Healthcare from $390.00 to $445.00 and gave the company an “overweight” rating in a research note on Thursday. Bank of America boosted their target price on HCA Healthcare from $375.00 to $410.00 and gave the company a “neutral” rating in a research note on Wednesday, September 10th. Finally, Stephens raised HCA Healthcare to a “strong-buy” rating in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $407.75.

Insider Buying and Selling

In related news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.